For pediatric JIA and plaque psoriasis, the approved dosing is weight-based (0.8 mg/kg) to ensure appropriate exposure in growing children. In contrast, adult indications for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis have been established with a fixed dose (50 mg) that has been shown to be effective and safe across a wide range of adult body weights.
About this Tool
The Enbrel® (etanercept) Dosing Calculator is an educational resource designed to help healthcare professionals determine appropriate dosing schedules based on approved indications and patient characteristics. This guide provides supplementary information on how to interpret its outputs, understand dosing principles, and manage common clinical scenarios.
Outputs
When you use the calculator, it provides the following key information based on the data entered:
- Final Recommended Dose: The precise dose in milligrams (mg) for administration. For pediatric patients, this reflects the weight-based calculation, including the 50 mg maximum dose cap.
- Dosing Regimen: The frequency of administration (e.g., once weekly, twice weekly for induction).
- Indication-Specific Details: For conditions like adult plaque psoriasis, the output distinguishes between the initial induction phase and the subsequent maintenance phase.
- Formulation Guidance: Information on which Enbrel® formulations are suitable for preparing the recommended dose. Doses other than 25 mg or 50 mg require reconstitution from lyophilized powder vials.
How to Use
The calculator is designed for simplicity and accuracy. Follow these steps to obtain a dosing recommendation:
- Select Indication: Choose the appropriate clinical indication from the dropdown list (e.g., Rheumatoid Arthritis, Pediatric Plaque Psoriasis).
- Enter Patient Age: Input the patient's age in years. This is critical for pediatric indications, which have specific age restrictions (e.g., ≥2 years for JIA, ≥4 years for pediatric psoriasis).
- Enter Patient Weight: If a pediatric indication is selected, the weight input field will appear. Enter the patient's weight and select the correct unit (kg or lbs). Weight is required for mg/kg dosing.
- Review Results: The calculator will display the complete dosing regimen, safety information, and formulation notes based on the provided inputs.
Dosing Overview
Enbrel® dosing varies significantly by indication and patient population. The following table summarizes the standard dosing schedules supported by the calculator.
| Indication | Patient Population | Dose & Regimen |
|---|---|---|
| Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis | Adults | 50 mg once weekly |
| Plaque Psoriasis | Adults | Induction: 50 mg twice weekly for 3 months Maintenance: 50 mg once weekly |
| Polyarticular Juvenile Idiopathic Arthritis (JIA) | Pediatric (≥2 years) | 0.8 mg/kg once weekly (Max dose: 50 mg) |
| Plaque Psoriasis | Pediatric (≥4 years) | 0.8 mg/kg once weekly (Max dose: 50 mg) |
Switching
Switching a patient to Enbrel® from another biologic or DMARD, or vice-versa, is a clinical decision that requires careful consideration of the previous therapy's mechanism of action and half-life to minimize risks of infection or loss of efficacy. There is no one-size-fits-all protocol; decisions should be individualized based on disease activity, patient risk factors, and clinical guidelines. Always consult the prescribing information for both agents when planning a transition.
Missed Dose
If a patient misses a dose of Enbrel®, they should be instructed to take it as soon as they remember. The next dose should then be taken on their regularly scheduled day. Patients should be advised not to take two doses at the same time to make up for a missed dose. If they are unsure what to do, they should contact their healthcare provider.
Safety Alerts
BOXED WARNING
SERIOUS INFECTIONS: Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections, and infections due to other opportunistic pathogens. Discontinue Enbrel if a patient develops a serious infection or sepsis. Perform test for latent TB; if positive, start treatment for TB prior to starting Enbrel. Monitor all patients for active TB during treatment, even with initial negative test.
MALIGNANCIES: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including Enbrel.
MALIGNANCIES: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including Enbrel.
FAQ
Why is patient weight required for pediatric indications but not for adults?
What happens if the calculated pediatric dose is over 50 mg?
The maximum recommended single dose for pediatric patients is 50 mg. The calculator automatically caps any calculated dose at 50 mg. For example, if a child weighs 70 kg, the calculated dose (70 * 0.8) would be 56 mg, but the tool will recommend the maximum dose of 50 mg.
What is the purpose of the 3-month induction period for adult plaque psoriasis?
The induction phase, which involves administering 50 mg twice weekly, is designed to achieve a more rapid clinical response and disease control. After the initial 3 months, the frequency is reduced to a once-weekly maintenance schedule to sustain the therapeutic effect.
How is Enbrel® administered?
Enbrel® is administered as a subcutaneous (under the skin) injection. Patients or caregivers can be trained to perform the injection at home using a prefilled autoinjector (SureClick®), a prefilled syringe, or the AutoTouch® reusable autoinjector with Enbrel Mini® cartridges.
Can this calculator be used for off-label indications?
No. This tool is for educational purposes and is strictly limited to the indications and dosing regimens approved by regulatory agencies like the FDA. Use for any other condition or patient population is not supported and should not be guided by this calculator.
Are dose adjustments needed for patients with kidney or liver problems?
The effect of renal or hepatic impairment on the pharmacokinetics of etanercept has not been studied. The official prescribing information does not provide specific dose adjustment recommendations for these populations. Clinical judgment is required.
What is the minimum age for treatment with Enbrel®?
The minimum approved age varies by indication. According to the calculator's parameters, Enbrel® is for patients aged 2 years and older for polyarticular JIA and for patients aged 4 years and older for plaque psoriasis.
What Enbrel® formulations are available to deliver the dose?
Enbrel® is available in several single-dose formats: a 50 mg SureClick® autoinjector, a 50 mg prefilled syringe, a 25 mg prefilled syringe, and a 50 mg Enbrel Mini® cartridge. For doses that are not exactly 25 mg or 50 mg (such as weight-based pediatric doses), the 25 mg lyophilized powder vial must be used for reconstitution to draw up the specific required volume.
References
- ENBREL® (etanercept) Prescribing Information. Amgen Inc. U.S. Food and Drug Administration. Revised: 04/2021.
- Enbrel® for Healthcare Professionals. Amgen Inc. Accessed October 2023.
- Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1-26.
- Enbrel (etanercept) European public assessment report (EPAR). European Medicines Agency. Accessed October 2023.
This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified health provider with any questions you may have regarding a medical condition.
